ACRO Announces 2023 Officers and New Member
WASHINGTON, DC – Washington DC – ACRO is pleased to announce that its Board of Directors has elected Paul Kirchgraber, M.D., Executive…
WASHINGTON, DC – Washington DC – ACRO is pleased to announce that its Board of Directors has elected Paul Kirchgraber, M.D., Executive…
WASHINGTON, DC – Today, the Association of Clinical Research Organizations (ACRO)’s DCT Working Party releases the latest addition to its DCT Toolkit:…
WASHINGTON, DC – This week, the Association of Clinical Research Organizations (ACRO)’s Diversity and Inclusion in Clinical Trials committee is proud to…
Washington, DC — On March 16, 2022, ACRO’s Board of Directors was joined by more than 125 clinical research stakeholders – including…
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Jackie…
Washington, DC — The Association of Clinical Research Organizations (ACRO) congratulates Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) on the release…
Risk-based monitoring (RBM) is a powerful tool for efficiently ensuring patient safety and data integrity in a clinical trial, enhancing overall trial…
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Steve…
September 1, 2020 – (Washington, DC) – Clinical trial activities have traditionally centered around trial sites where patients travel for participation. This…
May 6, 2020 – (Washington, DC) – In an effort to fight the global COVID-19 pandemic, over 150 employees from clinical research…
Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, ACRO this week submitted extensive comments on recent FDA Guidance.Increasing the use of innovative RBM technologies helps make clinical trials safer, more efficient and higher quality. ACRO’s comments offer unique insights into the recent expansion of RBM implementation and call for further increasing the use of these oversight technologies.
The Association of Clinical Research Organizations (ACRO) is pleased to announce the expansion of its membership to include ERT, Oracle and Veeva. These new ACRO member companies, with their focus on digital technologies that enable global clinical trials, characterize the ongoing innovation and evolution of contemporary clinical research. ACRO now has 12 member companies.
Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Dr. Cynthia Verst,…
The Association of Clinical Research Organizations (ACRO) convenes discussion series that seeks to advance an industry with important health and economic impacts…
In May of 2017 the Board of Directors of the Association of Clinical Research Organizations, which represents the world’s leading clinical research…
The Association of Clinical Research Organizations (ACRO) highlights contributions to health and economy (Leeds, UK) – Facing unprecedented challenges associated with Brexit,…
WASHINGTON–(BUSINESS WIRE)–The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected John Ratliff, CEO of Covance Drug…
WASHINGTON – November 14, 2017 – As the Senate begins debate on a tax reform bill, the clinical research industry hopes that…
Washington, DC – October 24, 2017 – On October 19 ACRO Executive Director Doug Peddicord, Ph.D., testified at a public hearing of…
WASHINGTON–(BUSINESS WIRE)–The Association of Clinical Research Organizations (ACRO) applauds Research!America for a recently released survey on the public’s perception of clinical trials….